



Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/17
January 22, 2014

The National Stock Exchange of India Limited,
Exchange Plaza,
Bandra – Kurla Complex,
Bandra (East),
Mumbai- 400 051

Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100 India
T 91 80 2808 2808
F 91 80 2852 3423

www.biocon.com

"By Courier & Email"

Kind Attn: Mr. Hari K.

Dear Sir,

Subject: - Unaudited financial results for the quarter ended December 31, 2013

We are pleased to inform that the Board of Directors of the Company have approved the unaudited financial results for the quarter ended December 31, 2013, at its meeting held on January 22, 2014 at Bangalore. In compliance with the Clause 41 of the Listing Agreement, we are forwarding the following documents for your record:

A. Financial Results:

Unaudited financial results as per the format specified in the listing agreement, for

- a) Biocon Limited and its Subsidiaries (consolidated)
- b) Biocon Limited (standalone)
- c) Biocon Limited - segment report (consolidated)

B. Limited Review Report issued by the Statutory Auditors.

C. A press announcement relating to the results.

Request to kindly take this intimation on record.

Thanking you,
Yours faithfully,
For Biocon Limited,



Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
M: +91 9945315151
T: +91 80 2808 2037

By "Courier"
By email: cm1ist@nse.co.in

Encl. No of sheets: 1 + 16

BIOCON LIMITED
Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2013

Part I							(Rs in Lakhs)
Sl. No.	Particulars	3 months ended 31.12.2013	Preceding 3 months ended 30.09.2013	Corresponding 3 months ended 31.12.2012	Year to date figures for current period ended 31.12.2013	Year to date figures for previous period ended 31.12.2012	Previous Year ended 31.03.2013
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	a) Net Sales/ Income from Operations (Net of excise duty)	70,116	73,421	63,422	213,013	179,748	242,760
	b) Other Operating Income	612	660	869	1,865	5,074	5,770
	Total income from operations (net)	70,728	74,081	64,291	214,878	184,822	248,530
2	Expenses						
	a) Cost of materials consumed	27,338	27,971	27,145	82,291	72,872	100,189
	b) Purchases of stock in trade	3,601	3,618	1,883	9,546	5,056	6,931
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(1,464)	(2,092)	(1,932)	(2,499)	(1,068)	(2,652)
	d) Employee benefits expense	11,546	11,310	9,459	34,386	28,043	38,944
	e) Depreciation and amortisation expenses	5,130	5,009	4,613	14,964	13,343	17,930
	f) Other expenses (net)	12,125	15,688	12,708	39,996	36,832	50,820
	Total Expenses	58,276	61,504	53,876	178,684	155,078	212,162
3	Profit from operations before other income, finance costs and exceptional items (1-2)	12,452	12,577	10,415	36,194	29,744	36,368
4	Other Income	1,229	1,173	1,674	3,864	4,081	5,266
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	13,681	13,750	12,089	40,058	33,825	41,634
6	Finance Costs	26	34	287	98	715	810
7	Profit from ordinary activities after finance costs before exceptional items (5-6)	13,655	13,716	11,802	39,960	33,110	40,824
8	Exceptional Items (net) (refer note 2 and 3 below)	-	-	-	-	-	20,191
9	Profit from ordinary activities before tax (7+8)	13,655	13,716	11,802	39,960	33,110	61,015
10	Tax Expense	2,616	3,189	2,521	8,776	6,936	9,750
11	Net profit for the period / year (9-10)	11,039	10,527	9,281	31,184	26,174	51,265
12	Minority Interest	(540)	(312)	(105)	(1,120)	(153)	(383)
13	Net profit after tax and minority interest (11+12)	10,499	10,215	9,176	30,064	26,021	50,882
14	Paid-up equity share capital (Face value of Rs.5 each)	10,000	10,000	10,000	10,000	10,000	10,000
15	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						259,373
16	Earnings per share (of Rs 5 each) (not annualised)						
	(a) Basic	5.35	5.21	4.68	15.33	13.29	25.99
	(b) Diluted	5.31	5.17	4.65	15.21	13.19	25.75
	See accompanying note to the financial results						
Part II							
Select information for the period							
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	Number of shares	78,051,554	78,051,554	78,075,854	78,051,554	78,075,854	78,075,854
	Percentage of shareholding	39.03%	39.03%	39.04%	39.03%	39.04%	39.04%
2	Promoters and promoter group shareholding						
	a) Pledged / encumbered						
	Number of shares	40,000	40,000	-	40,000	-	-
	Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	0.03%	0.03%	-	0.03%	-	-
	Percentage of shares (as a % of the total share capital of the Company)	0.02%	0.02%	-	0.02%	-	-
	b) Non-encumbered						
	Number of shares	121,908,446	121,908,446	121,924,146	121,908,446	121,924,146	121,924,146
	Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	99.97%	99.97%	100%	99.97%	100%	100%
	Percentage of shares (as a % of the total share capital of the Company)	60.95%	60.95%	60.96%	60.95%	60.96%	60.96%



1/16

BIOCON LIMITED
Registered office: 20th KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2013

Part I

(Rs in Lakhs)

Sl. No.	Particulars	3 months ended 31.12.2013	Preceding 3 months ended 30.09.2013 (also refer note 5 below)	Corresponding 3 months ended 31.12.2012	Year to date figures for current period ended 31.12.2013 (also refer note 5 below)	Year to date figures for previous period ended 31.12.2012	Previous Year ended 31.03.2013
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	a) Net Sales/ Income from Operations (Net of excise duty)	50,344	53,417	48,691	156,050	137,991	183,748
	b) Other Operating Income	2,286	2,524	1,979	7,057	8,230	10,052
	Total income from operations (net)	52,630	55,941	50,670	163,107	146,221	193,800
2	Expenses						
	a) Cost of materials consumed	22,341	22,990	22,132	68,088	61,151	82,999
	b) Purchases of stock in trade	3,372	3,400	2,421	8,840	6,222	8,570
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(1,131)	(2,329)	(656)	(2,338)	474	(1,790)
	d) Employee benefits expense	6,543	6,589	5,334	19,710	16,187	22,762
	e) Depreciation and amortisation expenses	3,131	3,021	2,392	9,050	7,117	9,508
	f) Other expenses (net)	11,592	12,393	10,735	34,429	29,647	40,690
	Total Expenses	45,848	46,064	42,358	137,779	120,798	162,739
3	Profit from operations before other income, finance costs and exceptional items (1-2)	6,782	9,877	8,312	25,328	25,423	31,061
4	Other Income	1,072	2,030	1,953	5,678	4,513	5,147
5	Profit from ordinary activities before finance costs and exceptional items (3+4)	7,854	11,907	10,265	31,006	29,936	36,208
6	Finance Costs	18	24	1	64	74	123
7	Profit from ordinary activities after finance costs before exceptional items (5-6)	7,836	11,883	10,264	30,942	29,862	36,085
8	Exceptional items (refer note 3 below)	-	-	-	-	-	1,385
9	Profit from ordinary activities before tax (7+8)	7,836	11,883	10,264	30,942	29,862	34,700
10	Tax Expense	1,840	2,895	2,243	7,185	6,121	7,130
11	Net profit for the period / year (9-10)	5,996	8,988	8,021	23,757	23,741	27,570
12	Impact of scheme of merger for earlier period (refer note 5 below)	-	554	-	554	-	-
13	Profit for the period after giving impact of scheme of merger for earlier year (11+12)	5,996	9,542	8,021	24,311	23,741	27,570
14	Paid-up equity share capital (Face Value of Rs.5 each)	10,000	10,000	10,000	10,000	10,000	10,000
15	Reserve excluding revaluation reserves as per balance sheet of previous accounting year						210,594
16	Earnings per share (of Rs 5 each) (not annualised)						
	(a) Basic (after giving impact of scheme of merger for earlier year)	3.06	4.87	4.10	12.39	12.13	14.08
	(b) Diluted (after giving impact of scheme of merger for earlier year)	3.03	4.83	4.07	12.30	12.04	13.95
	(c) Basic (before giving impact of scheme of merger for earlier year)	3.06	4.87	4.10	12.11	12.13	14.08
	(d) Diluted (before giving impact of scheme of merger for earlier year)	3.03	4.83	4.07	12.02	12.04	13.95
	See accompanying note to the financial results						

Part II

Select information for the period

A

PARTICULARS OF SHAREHOLDING

1

Public shareholding

Number of shares

78,051,554

78,051,554

78,075,854

78,051,554

78,075,854

78,075,854

Percentage of shareholding

39.03%

39.03%

39.04%

39.03%

39.04%

39.04%

2

Promoters and promoter group shareholding

a) Pledged/encumbered

Number of shares

40,000

40,000

-

40,000

-

-

Percentage of shares (as a % of the total shareholding of the promoter and promoter group)

0.03%

0.03%

-

0.03%

-

-

Percentage of shares (as a % of the total share capital of the Company)

0.02%

0.02%

-

0.02%

-

-

b) Non-encumbered

Number of shares

121,908,446

121,908,446

121,924,146

121,908,446

121,924,146

121,924,146

Percentage of shares (as a % of the total shareholding of the promoter and promoter group)

99.97%

99.97%

100.00%

99.97%

100.00%

100.00%

Percentage of shares (as a % of the total share capital of the Company)

60.95%



60.95%

60.96%

60.95%

60.96%

60.96%



2/16



BIOCON LIMITED

Registered office : 20TH KM HOSUR ROAD, ELECTRONIC CITY P.O., BANGALORE - 560 100

SEGMENT DETAILS OF CONSOLIDATED UNAUDITED RESULTS FOR THE

QUARTER AND NINE MONTH PERIOD ENDED DECEMBER 31, 2013

<u>Particulars</u>	(Rs. in Lakhs)	3 months ended 31.12.2013 (Unaudited)	Preceding 3 months ended 30.09.2013 (Unaudited)	Corresponding 3 months ended 31.12.2012 (Unaudited)	Year to date figures for current period ended 31.12.2013 (Unaudited)	Year to date figures for previous period ended 31.12.2012 (Unaudited)	Previous Year ended 31.03.2013 (Audited)
Segment revenue							
a. Pharma		52,116	54,991	50,132	161,448	144,993	191,831
b. Contract Research & Manufacturing Services		19,028	19,567	14,626	54,629	41,462	58,829
Total		71,144	74,558	64,758	216,077	186,455	250,660
Less: Inter-segment revenue		416	477	467	1,199	1,633	2,130
Net sales / Income from continuing operations		70,728	74,081	64,291	214,878	184,822	248,530
Segment results							
Profit before interest, depreciation and tax from each segment							
a. Pharma		20,970	22,915	19,665	65,698	57,156	75,444
b. Contract Research & Manufacturing Services		7,513	7,532	5,577	20,439	15,591	21,081
Total		28,483	30,447	25,242	86,137	72,747	96,525
Less: Interest		26	34	287	98	715	810
Depreciation and amortisation		5,130	5,009	4,613	14,964	13,343	17,930
Unallocated corporate expenses		10,901	12,861	10,214	34,979	29,660	42,227
Unallocated corporate income		(1,229)	(1,173)	(1,674)	(3,864)	(4,081)	(5,266)
Profit before tax and before exceptional items		13,555	13,716	11,802	39,960	33,110	40,824
Capital employed							
a. Pharma		154,919	136,455	123,036	154,919	123,036	128,336
b. Contract Research & Manufacturing Services		63,082	59,119	37,987	63,082	37,987	55,045
c. Unallocable		93,250	104,481	93,967	93,250	93,967	92,612
d. Minority interest		(7,647)	(7,110)	(533)	(7,647)	(533)	(6,530)
Total capital employed		303,604	292,945	254,457	303,604	254,457	269,463



3/16

Notes:

1. The unaudited financial results of the Company and the unaudited consolidated financial results for the quarter and nine months ended December 31, 2013 have been subjected to limited review by the statutory auditors. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on January 22, 2014.

2. During the year ended March 31, 2012, based on an evaluation of the prevalent regulatory framework, industry practices and ethics/governance requirements relating to clinical trials and the regulatory submissions already initiated / filed, Biocon SA, a wholly owned subsidiary of the Company (together referred to as 'Biocon'), had determined that it had continuing obligations to complete clinical development and regulatory activities relating to Biocon's Biosimilar Insulin portfolio comprising of Biosimilar Insulin and Biosimilar Insulin Analogs. Accordingly, pursuant to the termination of the customer contract in March 2012, Biocon deferred the remainder of the upfront amounts received from the customer, to be recognized in the consolidated statement of profit and loss in subsequent periods in line with costs incurred towards such clinical trials and development activities.

In February 2013, Biocon SA entered into an agreement with another customer for the global development and commercialization of Biosimilar Insulin Analogs (the Agreement), granting the customer exclusive rights to commercialize Biosimilar Insulin Analogs in certain countries. The clinical development and regulatory activities in respect of such Biosimilar Insulin Analogs is now being carried out in accordance with the Agreement. As such, Biocon has therefore determined that it does not have continuing obligations for clinical trials and development activities in respect of Biosimilar Insulin Analogs. Accordingly, based on an allocation in proportion of estimated future development spends on these programs, Rs 21,501 lakhs of deferred revenues allocated to Biosimilar Insulin Analogs (net of amounts already recognized in the consolidated statement of profit and loss) was recognized as an exceptional income in the consolidated statement of profit and loss for the year ended March 31, 2013 and is disclosed under exceptional items. Considering that Biocon has continuing obligations in respect of Biosimilar Insulin, the remainder of deferred amounts as at March 31, 2013, of Rs 28,001 lakhs, continues to be recognized in the consolidated statement of profit and loss in line with costs to be incurred towards clinical trials and development activities of Biosimilar Insulin. For the quarter ended December 31, 2013 and and September 30, 2013, of the deferred amounts, Rs 197 lakhs and Rs 614 lakhs, respectively have been netted off against expenses incurred towards such clinical trial and development activities.

The statutory auditors of the Company have drawn an Emphasis of Matter in this regard, in their Limited Review report on the consolidated unaudited financial results.

3. Pursuant to certain developments, on a prudent basis, the Company created a provision of Rs 1,385 lakhs and Rs 1,310 Lakhs for diminution, in the value of investments in Iatrica Inc in the standalone and consolidated financial statements, respectively for the year ended March 31, 2013.

4. Total income from operations for nine months period ended December 31, 2012, and for the year ended March 31, 2013 (standalone and consolidated) include Rs 3,064 Lakhs, towards one time income / compensation from few parties.



4/
16

5. On July 25, 2012, the Board of Directors of the Company approved a scheme of amalgamation ('the Scheme') of Biocon Biopharmaceuticals Limited ("BBL"), a wholly owned subsidiary, with the Company under sections 391 and 394 of the Companies Act, 1956. During the quarter ended September 30, 2013, the Honorable High Court of Karnataka ('the Court') approved the aforesaid Scheme with Appointed Date as April 1, 2012.

Accordingly, the assets and liabilities, and Deficit in the Statement of Profit and Loss of BBL of Rs 1,028 lakhs as at Appointed Date have been recorded at their carrying values under the Pooling of Interest method as prescribed by Accounting Standard 14 - Accounting for Amalgamation ('AS 14'), and difference between value of investments and the amount of share capital of BBL amounting to Rs 357 lakhs has been debited to the Reserves and Surplus of the Company.

Post receipt of the requisite approvals, the Company has considered the operations of BBL from April 1, 2012 as its own operations. Accordingly, profit after tax amounting to Rs 554 lakhs (net of tax of Rs 579 lakhs), relating to operations of BBL from April 1, 2012 to March 31, 2013, have been accounted for in the standalone results nine months ended December 31, 2013.

6. Segment Reporting :


- Standalone financial results: The Company operates in a single business segment of biopharmaceuticals.
- Consolidated financial results: The primary segment reporting has been performed on the basis of business segments. Segments have been identified and reported based on the nature of products, risks and returns, organizational structure and internal financial reporting systems.

7. Information on investor complaints:

	3 months ended 31.12.2013
Pending at the beginning of the quarter	-
Received during the quarter	18
Disposed during the quarter	18
Remaining unresolved at the end of the quarter	-

8. Prior period / year figures have been reclassified wherever required to conform to the classification of the current period.

For and on behalf of the Board of Directors of Biocon Limited



Kiran Mazumdar Shaw
Chairman and Managing Director

Bangalore,
January 22, 2014




5/16

Limited Review Report

Review Report to
The Board of Directors
Biocon Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Biocon Limited ('the Company') and its subsidiaries, joint venture and associate (together, 'the Group'), for the quarter ended December 31, 2013 (the "Statement"), being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not review revenues (including other income) and assets of Rs. 518 Lakhs and Rs. 57,441 Lakhs respectively, relating to one subsidiary, included in the accompanying unaudited consolidated financial results for the quarter ended December 31, 2013, whose financial information has been reviewed by other auditor and whose report has been furnished to us. Our conclusion on the unaudited quarterly financial results, in so far as it relates to such subsidiary is based solely on the report of the other auditor.
4. Without qualifying our conclusion, we draw attention to note 2 in the attached statement of unaudited consolidated financial results regarding management's decision to defer recognition of amounts in the consolidated statement of profit and loss, pertaining to payments received pursuant to the Termination & Transition Agreement entered into with a customer for reasons as more fully discussed in the aforesaid note. As further discussed in the said note, out of the deferred amount, Rs. 197 Lakhs has been netted off against expenses incurred during the quarter ended December 31, 2013, towards such clinical trial and development activities. Our auditors' report for the year ended March 31, 2013 also included a matter of emphasis in this regard.
5. Based on our review conducted as above and on consideration of report of other auditor on the unaudited separate quarterly financial results and on the other financial information of the component, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", [notified under the Companies Act, 1956 read with General Circular 15/2013

6/16




S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

dated 13 September 2013, issued by the Ministry of Corporate Affairs, in respect of Section 133 of the Companies Act, 2013], and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. Batliboi & Associates LLP
ICAI Firm registration number: 101049W
Chartered Accountants



per Aditya Vikram Bhauwala
Partner
Membership No.: 208382



Place: Bangalore
Date: January 22, 2014


7/16

Limited Review Report

Review Report to
The Board of Directors
Biocon Limited

1. We have reviewed the accompanying statement of unaudited financial results of Biocon Limited ('the Company') for the quarter ended December 31, 2013 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", [notified under the Companies Act, 1956 read with General Circular 15/2013 dated 13 September 2013, issued by the Ministry of Corporate Affairs, in respect of Section 133 of the Companies Act, 2013], and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. Batliboi & Associates LLP
ICAI Firm registration number: 101049W
Chartered Accountants


per Aditya Vikram Bhauwala
Partner
Membership No.: 208382



Place: Bangalore
Date: January 22, 2014

8/16



Biocon delivers 16% growth led by Research Services & Branded Formulations

**9MFY14 Performance: Revenues at ₹ 2,187 Crores; EBITDA at ₹ 550 Crores;
PAT at ₹ 301 Crores**

Bengaluru, India: January 22, 2014

Commenting on the quarterly performance and highlights, Chairman and Managing Director, Kiran Mazumdar-Shaw stated, "Q3 FY14 has been a very eventful quarter for us, with several research milestones across our novel molecules and biosimilars portfolio. The key highlight was the DCGI approval for our biosimilar Trastuzumab, which paved the way for its commercial launch in India as CANMAb™. CANMAb™ is not only the world's first biosimilar Trastuzumab, but is also the most affordable worldwide. We have also strengthened our R&D pipeline with 2 new alliances giving us access to novel technology platforms.

The performance of the Biopharmaceuticals segment has been steady as we continue our efforts to optimise the product basket. We have witnessed sustained business momentum in Research Services, and a return to growth for our Branded Formulations vertical. Our investment efforts in Malaysia continue and we are on track to commission our insulin facility in FY15. We expect to close this financial year with a strong performance across business verticals."

Highlights:

- Revenue growth in 9M FY14 reflects the strength of our differentiated portfolios
 - ❖ Biopharmaceuticals segment: 14% YoY
 - ❖ Research Services segment: 35% YoY
- 9MFY14 Group EBITDA and PAT margins at 25% and 14% respectively
- R&D investments for 9MFY14: 102 Crores (6% of Biopharmaceutical segment sales)
- Announced the launch of CANMAb™, world's first biosimilar Trastuzumab, in India
- Strategic partnerships with:
 - Quark Pharmaceuticals to develop siRNA based novel therapeutics
 - Advaxis Inc. for a novel cancer immunotherapy
- Ranked at No 6. in the 'Global Top 20 Employers' list for Bio pharma sector by the Science Magazine, 2013

Quarterly Business Performance

Financial Highlights: Q3 FY14 (In ₹ Crores)

Revenue : 719	Revenue Breakup:
R&D Expenses: 20 (4% of Biopharmaceutical segment sales)	• Biopharmaceuticals: 517
EBITDA: 187 (EBITDA Margin: 26%)	• Research Services: 183
PAT: 105 (PAT Margin: 15%)	• Other Income: 19

Biopharmaceuticals

The Biopharmaceuticals segment delivered a growth of 9% YoY at Constant Exchange Rate (CER) during 9M FY14. For Q3 FY14, at CER, the segment performance declined 2% YoY.

Small Molecules

As indicated earlier, the small molecules portfolio is currently being optimized to balance margin accretion with growth platforms. We have seen good momentum in Immunosuppressants and Orlistat, while the changing product mix for statins have helped balance out the headwinds in the industry.

Biosimilars

Our biosimilar Insulins portfolio continues to deliver strong growth. Our generic rh-Insulin is now approved in over 50 countries. Along with our partner Mylan, we continue with the groundwork to initiate a global Phase III trial for our generic Insulin Glargine.

We have announced the launch of CANMAb™, our biosimilar Trastuzumab in India. Our product is the first biosimilar Trastuzumab to be commercialized anywhere in the world; and comes with robust data from a 2 year long Phase III biosimilarity trial conducted in India on over 130 patients. Keeping the emerging market needs in perspective, we have launched the drug in two strengths (150 mg and 440 mg). The 150 mg presentation will help eliminate drug wastage and enable additional savings for patients, when used in conjunction with the standard 440 mg vial. CANMAb™ will be sold in India through Biocon's Oncotherapeutics division under the Branded Formulations vertical and will be available to patients in early February 2014.

Branded Formulations

The Branded Formulations vertical grew at 15% YoY in Q3 FY14, vis-à-vis the industry growth of 5% YoY, closing the period with 99 Crs in sales. The impasse between the trade and the pharma companies has largely been resolved, and we have seen growth return to the market driven by chronic therapies.

The growth for this quarter has been led by our flagship brands of Basalog® Insupen®, BioMab EGFR® and Abraxane®. In addition, we have seen very enthusiastic uptake of Cytosorb®, a novel therapy in sepsis management that we had launched last quarter.

We have signed a licensing and co-development agreement with Advaxis Inc. for ADXS-HPV, a novel cancer immunotherapy to treat Human Papilloma Virus (HPV)-associated cervical cancer in India and key emerging markets.

Novel Molecules

We commenced global trials for our oral insulin (IN 105) program in the US. Our partnership with BMS on this asset continues, in line with their decision to retain this asset.

We entered into a strategic collaboration with Quark Pharmaceuticals this quarter, to develop a range of siRNA based novel therapeutics. This co-development alliance will leverage Quark's proprietary technology platform to target various unmet medical needs. The lead candidate in this program is QPI-1007, a novel siRNA drug candidate for ophthalmic conditions.

Research Services

The Research Services segment grew 22% YoY and 15% YoY at Constant Exchange Rate (CER) for 9M FY14 and Q3 FY14 respectively, with widespread growth across our service platforms.

Commenting on this performance, Peter Bains, Director Syngene International, said, *"We are pleased with the strong growth delivered by Research Services through 9MFY14. This reflects sustained business momentum and an increasing penetration of our integrated service offerings. As pharma and biopharma continue to evolve their R&D models, we see a sustained emphasis on collaborative externalization. In addition, there is increasing interest from allied sectors such as nutrition, consumer & animal health and agrichemicals to create partnerships between our research and development capabilities and their product pipelines. I am also pleased to report that Syngene has successfully cleared its first USFDA audit of its quality systems, with no observations or 483s. The audit was triggered by an application from one of our existing clients, and gives further credence to the world class quality systems, underpinning our service platforms."*

Outlook

The outlook for FY14 remains positive while we strive to balance our revenue growth and R&D spend. Our portfolio and cost optimization initiatives continue, helping us manage our margins more effectively. We continue to invest in our R&D pipeline, and the several milestones achieved over the course of this year are indicative of the growth opportunities ahead of us. Our Malaysia facility is on track for commissioning in FY15.

About Biocon

Established in 1978, Biocon Limited, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin (INSUGEN®), Glargine (BASALOG®), as well as MAbs like BioMAb-EGFR® for head & neck cancer and Alzumab™ for Psoriasis. It has now successfully developed the world's first biosimilar



Trastuzumab, being introduced as CANMab™ for HER2 positive breast cancer in India, in 2014.
www.biocon.com

Disclaimer

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, our directors, nor any of our affiliates, have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Earnings Call

The company will conduct an hour long call at **3:30 PM IST on January 23, 2014** where the senior management will discuss the company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The **dial-in number for this call is +91-22-6629 5889/ 3065 2542**. Other toll numbers are listed in the conference call invite which is posted on the company website www.biocon.com. The operator will provide instructions on asking questions before the start of the call. To receive reminders for the earnings call, you can register [here](#). A replay of this call will also be available from **January 23, 2014 – January 31, 2014** on **+91 22 3065 1212, Playback ID: 311121**. The transcript of the conference call will be posted on the company website within 7 working days of the investor conference call. **Encl.: Fact Sheet - Consolidated Income Statement and Balance Sheet (Indian GAAP)**

Contact Information:

Investor Relations

Saurabh Paliwal
+91 95383 80801
saurabh.paliwal@biocon.com

Sweta Pachlangiya
+91 96865 09372
sweta.pachlangiya@syngeneintl.com

Media Relations

Seema Ahuja
+91 99723 17792
seema.ahuja@biocon.com

Rumman Ahmed
+91 98451 04173
rumman.ahmed@biocon.com

BIOCON GROUP

FACT SHEET

December - 2013

**YTD FY 2014 vs. YTD FY 2013
Q3 FY 2014 vs. Q3 FY 2013**

13/
16

BIOCON LIMITED (CONSOLIDATED) UNAUDITED BALANCE SHEET		(Rs. Crores)
	December 31, 2013	March 31, 2013
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,936	2,595
	3,036	2,695
Minority interest	76	65
Non-current liabilities		
(a) Long-term borrowings	475	164
(b) Deferred tax liability (net)	35	41
(c) Other long-term liabilities	550	424
(d) Long-term provisions	7	4
	1,067	633
Current liabilities		
(a) Short-term borrowings	62	85
(b) Trade payables	390	345
(c) Other current liabilities	359	347
(d) Short-term provisions	102	246
	913	1,023
TOTAL	5,092	4,416
ASSETS		
Non-current assets		
(a) Fixed assets	2,337	1,811
(b) Goodwill	12	12
(c) Non-current investments	65	64
(d) Long term loans and advances	274	248
(e) Other non-current assets	52	41
	2,740	2,176
Current assets		
(a) Current Investments	388	522
(b) Inventories	443	398
(c) Trade receivables	621	510
(d) Cash and cash equivalents	661	673
(e) Short term loans and advances	159	81
(f) Other current assets	80	56
	2,352	2,240
TOTAL	5,092	4,416

14/16

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	9M FY 14	9M FY 13	Variance
INCOME			
Biopharmaceuticals	1,603	1,406	14%
Biopharma *	1,304	1,143	14%
Branded formulations - India	299	263	14%
Contract research	526	391	35%
Total Sales	2,129	1,797	18%
Other income	58	92	-37%
Total Revenue	2,187	1,889	16%
EXPENDITURE			
Material & Power costs	1,016	877	16%
Staff costs	317	259	22%
Research & Development **	102	121	-16%
Other expenses	202	160	26%
Manufacturing, staff & other expenses	1,637	1,417	16%
EBITDA	550	472	17%
Interest & Finance charges	1	7	
Depreciation & Amortisation	149	134	11%
PBT	400	331	21%
Taxes	88	69	28%
NET PROFIT BEFORE MINORITY INTEREST	312	262	19%
Minority interest	11	2	
NET PROFIT FOR THE PERIOD	301	260	16%
EPS Rs.	15.0	13.3	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharmaceuticals Income includes:			
Licensing Income	15	23	
** Gross Research & Development expenses	114	149	

15/16

BIOCON LIMITED (CONSOLIDATED) UNAUDITED PROFIT & LOSS STATEMENT				(Rs. Crores)
Particulars	Q3 FY 14	Q3 FY 13	Variance	
INCOME				
Biopharmaceuticals	517	495	4%	
Biopharma *	418	409	2%	
Branded formulations - India	99	86	15%	
Contract research	183	140	31%	
Total Sales	700	635	10%	
Other income	19	25	-24%	
TOTAL REVENUE	719	660	9%	
EXPENDITURE				
Material & Power costs	338	307	10%	
Staff costs	107	88	22%	
Research & Development **	20	43	-53%	
Other expenses	67	55	22%	
Manufacturing, staff & other expenses	532	493	8%	
EBITDA	187	167	12%	
Interest & Finance charges	-	3		
Depreciation & Amortisation	51	46	11%	
PBT	136	118	15%	
Taxes	26	25	4%	
NET PROFIT BEFORE MINORITY INTEREST	110	93	18%	
Minority interest	5	1		
NET PROFIT FOR THE PERIOD	105	92	14%	
EPS Rs.	5.2	4.7		
Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers				
* Biopharma Income includes:				
Licensing Income	4	9		
** Gross Research & Development expenses	23	49		

16/16